Literature DB >> 10702390

Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation.

L Huang1, J Xu, D J Wood, M H Zheng.   

Abstract

Giant cell tumor of bone (GCT) is a rare primary osteolytic tumor of bone that is characterized by massive tissue destruction at the epiphysis of long bones. There is no evidence that tumor cells themselves are capable of bone destruction; instead, it appears that the tumor cells of GCT act by promoting osteoclastogenesis and, as a consequence, osteoclastic bone resorption. However, the mechanism by which this is achieved is not understood. Here we attempted to determine whether osteoprotegerin ligand (OPGL), the factor that is necessary and essential for osteoclastogenesis, is involved in tumor cell-recruited osteoclast-like giant cell formation in GCT. Using fluorescence in situ hybridization, we sought to determine mRNA expression of OPGL, its receptor RANK, and its decoy receptor OPG in three major cell types of GCT. We demonstrated that OPG mRNA was expressed in all three cell types of GCT, OPGL transcripts were mainly detected in spindle-shaped stromal-like tumor cells, whereas RANK was expressed only in macrophage-like mononuclear cells and multinuclear osteoclast-like giant cells. By semiquantitative RT-PCR, we also showed that the level of OPGL mRNA in GCT is much higher than that in normal bone and osteogenic osteosarcoma. In contrast, a similar level of OPG transcripts was detected in these three kinds of tissues, and RANK mRNA was detectable only in GCT tissues. We have further examined the regulation of gene expression of OPGL and OPG in tumor cells in response to osteotropic hormones. Administration of 1,25(OH)(2)D(3) and dexamethasone resulted in maximum up-regulation of OPGL level and down-regulation of OPG level in cultured GCT stromal-like tumor cells and the mouse bone marrow-derived ST-2 stromal cell line. Furthermore, we have shown that tumor cells of GCT induce differentiation of RANK-expressing myeloid RAW(264.7) cells into osteoclast-like cells in the presence of 1,25(OH)(2)D(3) and dexamethasone. Our findings suggest that OPGL is involved in the tumor cell-induced osteoclast-like cell formation in GCT. The ratio of OPGL/OPG by tumor cells may contribute to the degree of osteoclastogenesis and bone resorption.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10702390      PMCID: PMC1876848          DOI: 10.1016/s0002-9440(10)64942-5

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  29 in total

Review 1.  What's new in osteoclast ontogeny?

Authors:  M H Zheng; G C Nicholson; A Warton; J M Papadimitriou
Journal:  Pathol Res Pract       Date:  1991-01       Impact factor: 3.250

Review 2.  Modulation of osteoclast differentiation.

Authors:  T Suda; N Takahashi; T J Martin
Journal:  Endocr Rev       Date:  1992-02       Impact factor: 19.871

3.  Telomeric fusion is a major cytogenetic aberration of giant cell tumors of bone.

Authors:  M H Zheng; P Siu; J M Papadimitriou; D J Wood; A R Murch
Journal:  Pathology       Date:  1999-11       Impact factor: 5.306

4.  An immunohistological study of giant-cell tumour of bone: evidence for an osteoclast origin of the giant cells.

Authors:  N A Athanasou; E Bliss; K C Gatter; A Heryet; C G Woods; J O McGee
Journal:  J Pathol       Date:  1985-11       Impact factor: 7.996

5.  The bone marrow-derived stromal cell lines MC3T3-G2/PA6 and ST2 support osteoclast-like cell differentiation in cocultures with mouse spleen cells.

Authors:  N Udagawa; N Takahashi; T Akatsu; T Sasaki; A Yamaguchi; H Kodama; T J Martin; T Suda
Journal:  Endocrinology       Date:  1989-10       Impact factor: 4.736

6.  Human giant cell tumors of bone identification and characterization of cell types.

Authors:  S R Goldring; M S Roelke; K K Petrison; A K Bhan
Journal:  J Clin Invest       Date:  1987-02       Impact factor: 14.808

Review 7.  What's new in the role of cytokines on osteoblast proliferation and differentiation?

Authors:  M H Zheng; D J Wood; J M Papadimitriou
Journal:  Pathol Res Pract       Date:  1992-12       Impact factor: 3.250

8.  Production of matrix metalloproteinases 2 and 3 (stromelysin) by stromal cells of giant cell tumor of bone.

Authors:  Y Sasaguri; S Komiya; K Sugama; K Suzuki; A Inoue; M Morimatsu; H Nagase
Journal:  Am J Pathol       Date:  1992-09       Impact factor: 4.307

9.  Detection of mRNA for carbonic anhydrase II in human osteoclast-like cells by in situ hybridization.

Authors:  M H Zheng; Y Fan; S Wysocki; D J Wood; J M Papadimitriou
Journal:  J Bone Miner Res       Date:  1993-01       Impact factor: 6.741

10.  Dexamethasone stimulates osteoclast-like cell formation by inhibiting granulocyte-macrophage colony-stimulating factor production in mouse bone marrow cultures.

Authors:  T Shuto; T Kukita; M Hirata; E Jimi; T Koga
Journal:  Endocrinology       Date:  1994-03       Impact factor: 4.736

View more
  71 in total

1.  Rapamycin inhibits osteoclast formation in giant cell tumor of bone through the C/EBPβ - MafB axis.

Authors:  Jeske J Smink; Per-Ulf Tunn; Achim Leutz
Journal:  J Mol Med (Berl)       Date:  2011-11-10       Impact factor: 4.599

Review 2.  Giant cell tumor of bone.

Authors:  Alan W Yasko
Journal:  Curr Oncol Rep       Date:  2002-11       Impact factor: 5.075

3.  Rab3D regulates a novel vesicular trafficking pathway that is required for osteoclastic bone resorption.

Authors:  Nathan J Pavlos; Jiake Xu; Dietmar Riedel; Joyce S G Yeoh; Steven L Teitelbaum; John M Papadimitriou; Reinhard Jahn; F Patrick Ross; Ming H Zheng
Journal:  Mol Cell Biol       Date:  2005-06       Impact factor: 4.272

Review 4.  Giant cell tumour of bone: morphological, biological and histogenetical aspects.

Authors:  Mathias Werner
Journal:  Int Orthop       Date:  2006-09-30       Impact factor: 3.075

5.  Collagenase expression and activity in the stromal cells from giant cell tumour of bone.

Authors:  Robert W Cowan; Isabella W Y Mak; Nigel Colterjohn; Gurmit Singh; Michelle Ghert
Journal:  Bone       Date:  2009-02-12       Impact factor: 4.398

6.  Histogenetic characterization of giant cell tumor of bone.

Authors:  Manuela Salerno; Sofia Avnet; Marco Alberghini; Armando Giunti; Nicola Baldini
Journal:  Clin Orthop Relat Res       Date:  2008-06-10       Impact factor: 4.176

Review 7.  Mechanisms of action of therapeutic antibodies for cancer.

Authors:  J M Redman; E M Hill; D AlDeghaither; L M Weiner
Journal:  Mol Immunol       Date:  2015-04-23       Impact factor: 4.407

Review 8.  Chronic inflammation in biomaterial-induced periprosthetic osteolysis: NF-κB as a therapeutic target.

Authors:  Tzu-hua Lin; Yasunobu Tamaki; Jukka Pajarinen; Heather A Waters; Deanna K Woo; Zhenyu Yao; Stuart B Goodman
Journal:  Acta Biomater       Date:  2013-10-01       Impact factor: 8.947

9.  The epidemiology of malignant giant cell tumors of bone: an analysis of data from the Surveillance, Epidemiology and End Results Program (1975-2004).

Authors:  Jennifer L Beebe-Dimmer; Karynsa Cetin; Jon P Fryzek; Scott M Schuetze; Kendra Schwartz
Journal:  Rare Tumors       Date:  2009-12-28

10.  Role of the VEGF-Flt-1-FAK pathway in the pathogenesis of osteoclastic bone destruction of giant cell tumors of bone.

Authors:  Yoshihiro Matsumoto; Yuko Okada; Jun-Ichi Fukushi; Satoshi Kamura; Toshifumi Fujiwara; Keiichiro Iida; Mihoko Koga; Shuichi Matsuda; Katsumi Harimaya; Akio Sakamoto; Yukihide Iwamoto
Journal:  J Orthop Surg Res       Date:  2010-11-09       Impact factor: 2.359

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.